Resolution Therapeutics to Present Innovative EMERALD Study at BASL Annual Meeting

Overview of the EMERALD Study

Resolution Therapeutics Ltd, a biopharmaceutical company specializing in innovative treatments for inflammatory and fibrotic diseases, is set to present the design of their EMERALD study at the British Association for the Study of the Liver (BASL) annual meeting in Belfast, Northern Ireland, from October 7 to 10, 2025. The EMERALD study is a pivotal multicentre Phase I/II clinical trial focused on evaluating the efficacy of RTX001, an engineered macrophage therapy aimed at treating patients suffering from end-stage liver disease.

Key Details of the Presentation

The Chief Investigator of the EMERALD study, Professor Jonathan Fallowfield from the University of Edinburgh, will be presenting a detailed poster on the study design during the conference. The session will take place on October 8, 2025, from 6:00 PM to 8:00 PM BST. The poster is titled "An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD)". This study seeks to enroll up to 25 patients at leading hepatology centers in the UK and Spain.

Study Objectives and Significance

The primary objective of the EMERALD study is to assess the safety and effectiveness of RTX001 in patients who have experienced hepatic decompensation. As the first clinical evaluation of Regenerative Macrophage Therapy in humans with advanced liver fibrosis, this study is groundbreaking. It aims to offer hope to patients suffering from conditions with severely limited treatment options and high mortality risk. Dr. Clifford Brass, Chief Medical Officer at Resolution Therapeutics, emphasized the importance of this trial, stating, "EMERALD is the first study where engineered Regenerative Macrophage Therapy is being evaluated in humans with advanced liver fibrosis. We are excited to share the study design and to be fully open for enrolment for these patients."

Importance of Regenerative Macrophage Therapy

RTX001, the therapy under investigation, is an engineered autologous regenerative macrophage product designed to enhance natural healing mechanisms in the liver. This novel therapy utilizes advanced technologies, involving IL-10-MMP9 mRNA, to amplify the therapeutic potential of macrophages in combating liver fibrosis and inflammation. Many patients suffering from end-stage liver disease find themselves with limited treatment avenues; thus, successful outcomes in this trial could lead to significantly improved patient management strategies.

Next Steps and Future of the Therapy

The EMERALD study has already marked a critical milestone by successfully dosing its first patient at the Royal Infirmary of Edinburgh. Continuous recruitment is anticipated, as the research team works diligently to enroll patients across multiple sites. Further information about the EMERALD study can be accessed at clinicaltrials.gov, with the identifier NCT06823713, and additional insights are available on the British Liver Trust website.

About Resolution Therapeutics

Resolution Therapeutics aims to redefine treatment paradigms for inflammatory and fibrotic diseases through its pioneering regenerative macrophage therapy. With a commitment to improving patient outcomes, the company is expanding its research to address various conditions beyond liver disease, such as graft-versus-host disease and lung fibrosis. The firm’s development of RTX001 represents a promising frontier in combating end-stage liver conditions, serving as a beacon of hope for patients and clinicians alike.

Resolution Therapeutics continues to engage with the medical community and potential partners to further its mission of advancing regenerative medicine.

For updates from the BASL conference and more details on the EMERALD study, stay connected through Resolution Therapeutics' official communication channels and visit their websites.